HDAC6 is frequently overexpressed in ER+ breast cancers (such as MCF‐7, ZR‐75‐1, and T‐47D), where it correlates with low tumor grade, smaller size, and hormone receptor positivity [79, 80]. Here, ESR1 is linked to breast carcinoma.